In this video, Motley Fool health-care analyst David Williamson takes a closer look at what has propelled Aegerion Pharmaceuticals (NASDAQ:AEGR) to new heights and what it means for its potential competitor Isis Pharmaceuticals (NASDAQ:IONS). He also discusses Merck's (NYSE:MRK) latest stumble, a failed study that may get an approved drug pulled from the market.

David Williamson has no positions in the stocks mentioned above. Follow him on Twitter @MotleyDavid

The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.